(R)-1-benzyl-3-(3-methoxybenzyl)piperazine | 1443434-19-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (R)-1-benzyl-3-(3-methoxybenzyl)piperazine
• CAS: 1443434-19-2
• 化学式: C₁₉H₂₄N₂O
• 分子量: 296.412
• InChiKey: KXQQGIIEKRTRLG-GOSISDBHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.71
• 重原子数：
  22.0
• 可旋转键数：
  5.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  24.5
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  (R)-1-benzyl-3-(3-methoxybenzyl)piperazine 在 吡啶 、 四磷十氧化物 、 三氯氧磷 作用下， 生成 (11aR)-2-benzyl-9-methoxy-3,4,11,11a-tetrahydro-1H-pyrazino[1,2-b]isoquinolin-6-one
  参考文献：
  名称：

  Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists

  摘要：

  The 5-HT2C receptor has been implicated as a critical regulator of appetite. Small molecule activation of the 5-HT2C receptor has been shown to affect food intake and regulate body weight gain in rodent models and more recently in human clinical trials. Therefore, 5-HT2C is a well validated target for anti-obesity therapy. The synthesis and structure-activity relationships of a series of novel tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists are presented. Several members of this series were identified as potent 5-HT2C receptor agonists with high functional selectivity against the 5-HT2A and 5-HT2B receptors and reduced food intake in an acute rat feeding model upon oral dosing. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.061
• 作为产物：
  描述：

  ethyl (R)-N-benzyl-N-(2-((tert-butoxycarbonyl)amino)-3-(3-methoxyphenyl)propanoyl)glycinate 在 盐酸 、 lithium aluminium tetrahydride 、 sodium carbonate 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 水 、 1,2-二氯乙烷 为溶剂， 生成 (R)-1-benzyl-3-(3-methoxybenzyl)piperazine
  参考文献：
  名称：

  Synthesis and SAR of potent and selective tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists

  摘要：

  The 5-HT2C receptor has been implicated as a critical regulator of appetite. Small molecule activation of the 5-HT2C receptor has been shown to affect food intake and regulate body weight gain in rodent models and more recently in human clinical trials. Therefore, 5-HT2C is a well validated target for anti-obesity therapy. The synthesis and structure-activity relationships of a series of novel tetrahydropyrazinoisoquinolinone 5-HT2C receptor agonists are presented. Several members of this series were identified as potent 5-HT2C receptor agonists with high functional selectivity against the 5-HT2A and 5-HT2B receptors and reduced food intake in an acute rat feeding model upon oral dosing. (c) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.04.061